135 related articles for article (PubMed ID: 26542332)
1. Youth Depression Alleviation-Augmentation with an anti-inflammatory agent (YoDA-A): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirin.
Quinn AL; Dean OM; Davey CG; Kerr M; Harrigan SM; Cotton SM; Chanen AM; Dodd S; Ratheesh A; Amminger GP; Phelan M; Williams A; Mackinnon A; Giorlando F; Baird S; Rice S; O'Shea M; Schäfer MR; Mullen E; Hetrick S; McGorry P; Berk M
Early Interv Psychiatry; 2018 Feb; 12(1):45-54. PubMed ID: 26542332
[TBL] [Abstract][Full Text] [Related]
2. Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin.
Berk M; Mohebbi M; Dean OM; Cotton SM; Chanen AM; Dodd S; Ratheesh A; Amminger GP; Phelan M; Weller A; Mackinnon A; Giorlando F; Baird S; Incerti L; Brodie RE; Ferguson NO; Rice S; Schäfer MR; Mullen E; Hetrick S; Kerr M; Harrigan SM; Quinn AL; Mazza C; McGorry P; Davey CG
BMC Med; 2020 Jan; 18(1):16. PubMed ID: 31948461
[TBL] [Abstract][Full Text] [Related]
3. The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial.
Davey CG; Chanen AM; Hetrick SE; Cotton SM; Ratheesh A; Amminger GP; Koutsogiannis J; Phelan M; Mullen E; Harrison BJ; Rice S; Parker AG; Dean OM; Weller A; Kerr M; Quinn AL; Catania L; Kazantzis N; McGorry PD; Berk M
Lancet Psychiatry; 2019 Sep; 6(9):735-744. PubMed ID: 31371212
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder.
Plank JR; Glover SC; Moloney BD; Hoeh NR; Sundram F; Sumner RL; Muthukumaraswamy S; Lin JC
Trials; 2022 Sep; 23(1):822. PubMed ID: 36175917
[TBL] [Abstract][Full Text] [Related]
5. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial.
Baune BT; Sampson E; Louise J; Hori H; Schubert KO; Clark SR; Mills NT; Fourrier C
Eur Neuropsychopharmacol; 2021 Dec; 53():34-46. PubMed ID: 34375789
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
Fourrier C; Sampson E; Mills NT; Baune BT
Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
[TBL] [Abstract][Full Text] [Related]
7. The Study of Ketamine for Youth Depression (SKY-D): study protocol for a randomised controlled trial of low-dose ketamine for young people with major depressive disorder.
Schwartz OS; Amminger P; Baune BT; Bedi G; Berk M; Cotton SM; Daglas-Georgiou R; Glozier N; Harrison B; Hermens DF; Jennings E; Lagopoulos J; Loo C; Mallawaarachchi S; Martin D; Phelan B; Read N; Rodgers A; Schmaal L; Somogyi AA; Thurston L; Weller A; Davey CG
Trials; 2023 Oct; 24(1):686. PubMed ID: 37875938
[TBL] [Abstract][Full Text] [Related]
8. The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): study protocol for a randomised control trial.
Davey CG; Chanen AM; Cotton SM; Hetrick SE; Kerr MJ; Berk M; Dean OM; Yuen K; Phelan M; Ratheesh A; Schäfer MR; Amminger GP; Parker AG; Piskulic D; Harrigan S; Mackinnon AJ; Harrison BJ; McGorry PD
Trials; 2014 Nov; 15():425. PubMed ID: 25370185
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of citalopram with aspirin for treating major depressive disorder, a double blind randomized placebo controlled clinical trial.
Ghanizadeh A; Hedayati A
Antiinflamm Antiallergy Agents Med Chem; 2014; 13(2):108-11. PubMed ID: 25091820
[TBL] [Abstract][Full Text] [Related]
11. Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study.
Kanchanatawan B; Tangwongchai S; Sughondhabhirom A; Suppapitiporn S; Hemrunrojn S; Carvalho AF; Maes M
Neurotox Res; 2018 Apr; 33(3):621-633. PubMed ID: 29327213
[TBL] [Abstract][Full Text] [Related]
12. A Double-Blind, Randomized, Placebo-Controlled Study of Aspirin and N-Acetylcysteine as Adjunctive Treatments for Bipolar Depression.
Bauer IE; Green C; Colpo GD; Teixeira AL; Selvaraj S; Durkin K; Zunta-Soares GB; Soares JC
J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30549489
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis.
Na KS; Lee KJ; Lee JS; Cho YS; Jung HY
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():79-85. PubMed ID: 24056287
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin add-on to escitalopram in patients with comorbid obesity and major depression (SIMCODE): study protocol of a multicentre, randomised, double-blind, placebo-controlled trial.
Otte C; Chae WR; Nowacki J; Kaczmarczyk M; Piber D; Roepke S; Märschenz S; Lischewski S; Schmidt S; Ettrich B; Grabe HJ; Hegerl U; Hinkelmann K; Hofmann T; Janowitz D; Junghanns K; Kahl KG; Klein JP; Krueger THC; Leicht G; Prvulovic D; Reif A; Schoettle D; Strauss M; Westermair A; Friede T; Gold SM
BMJ Open; 2020 Dec; 10(12):e040119. PubMed ID: 33262189
[TBL] [Abstract][Full Text] [Related]
15. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
[TBL] [Abstract][Full Text] [Related]
16. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
[TBL] [Abstract][Full Text] [Related]
17. Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.
Stewart TD; Hatch A; Largay K; Sheehan JJ; Marler SV; Berman RM; Nelson JC
J Affect Disord; 2014 Jun; 162():20-5. PubMed ID: 24766999
[TBL] [Abstract][Full Text] [Related]
18. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
19. Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial.
McAllister-Williams RH; Anderson IM; Finkelmeyer A; Gallagher P; Grunze HC; Haddad PM; Hughes T; Lloyd AJ; Mamasoula C; McColl E; Pearce S; Siddiqi N; Sinha BN; Steen N; Wainwright J; Winter FH; Ferrier IN; Watson S;
Lancet Psychiatry; 2016 Feb; 3(2):117-27. PubMed ID: 26727041
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial.
Berk M; Dean OM; Cotton SM; Jeavons S; Tanious M; Kohlmann K; Hewitt K; Moss K; Allwang C; Schapkaitz I; Robbins J; Cobb H; Ng F; Dodd S; Bush AI; Malhi GS
J Clin Psychiatry; 2014 Jun; 75(6):628-36. PubMed ID: 25004186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
